Mortality and Associated Risk Factors among In-Patients with Covid-19 in Douala, Cameroon: A Retrospective Cross-Sectional Study

Francois Adrien Bokalli1,2*, Fru McWright Chi2*, Ephesians Anutebeh2, Caven Ngoe2, Mbachan Takere2, Edwin Éwane2, Dieudonne Akanji2, Conrad Ékukole2, Marie-Solange Ndom3, Mireille-Laurent Endale3, David Mekolo1,4, Henry Luma5, Jacqueline Ze Minkande6, Marcelin Ngowe Ngowe7

1Specialised COVID-19 Treatment Centre Yassa, Douala, Cameroon
2Department of Medicine, Faculty of Health Sciences, University of Buea, Buea, Cameroon
3Department of Medicine, Laquintinie Hospital, Douala, Cameroon
4Intensive Care and Emergency Department, Laquintinie Hospital, Douala, Cameroon
5Department of Internal Medicine, Douala General Hospital, Douala, Cameroon
6Department of Surgery and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde, Yaounde, Cameroon
7Department of Surgery and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon

Email: *francois_boks@yahoo.fr, *chimcwright@gmail.com

How to cite this paper: Bokalli, F.A., Chi, F.M., Anutebeh, E., Ngoe, C., Takere, M., Éwane, E., Akanji, D., Ékukole, C., Ndom, M.-S., Endale, M.-L., Mekolo, D., Luma, H., Minkande, J.Z. and Ngowe, M.N. (2022) Mortality and Associated Risk Factors among In-Patients with Covid-19 in Douala, Cameroon: A Retrospective Cross-Sectional Study. Advances in Infectious Diseases, 12, 1-19. https://doi.org/10.4236/aid.2022.121001

Received: September 18, 2021
Accepted: January 18, 2022
Published: January 21, 2022

Copyright © 2022 by author(s) and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
http://creativecommons.org/licenses/by/4.0/

Abstract

Background: In March 2020, the World Health Organization declared the coronavirus disease 2019 a pandemic, this was caused by the Severe Acute Respiratory Syndrome Coronavirus 2. The overall mortality from this remains high, yet there are limited studies assessing the associated factors in Africa. Objective: To identify the factors associated with mortality in hospitalized COVID-19 patients in Douala, Cameroon. Method: We conducted a single-centre retrospective cross-sectional study by reviewing records of patients managed for COVID-19 between March and June 2020. Diagnosis was confirmed by real-time RT-PCR. Outcome of interest was mortality during hospitalization. We inputted and analyzed data using SPSS version 25.0, compared mortality between groups using the Chi’s squared test and the Fisher’s exact test where appropriately investigated for associations using the Logistic regression in a stepwise approach and alpha-value set at P = 0.05. Results: We analyzed 282 case files, 68% were males (M:F = 2:1) and a mean age of 52 (±15) years. We had an overall mortality of 31.5% (89/282 patients) and 54% (50/92 patients) admitted in the ICU died. Patients aged 0 - 39 years had a significantly lesser odds of mortality compared to those > 70 years (OR:...
Hemodynamic instability at presentation showed association with mortality (P < 0.001) ranging as follows; moderate disease OR: 7.3 (2.4 - 21.8) versus Sepsis OR: 317 (58.3 - 1729.3). Mortality was as high as 63% in those with alveolar consolidation on CT scan (OR: 0.3 (0.1 - 0.6)), those with a 75% - 100% involvement of the lung parenchyma had a significantly higher mortality compared with those of <10% involvement (OR: 0.02 (0.01 - 0.06) P < 0.001). About 55% of patients placed on supplemental oxygen died (OR: 0.2 (0.1 - 0.3)) and up to 80% (OR: 0.1 (0.01 - 1.0)) of intubated patients died. In the ICU population, placement on non-invasive mechanical ventilation (AOR: 0.5 (0.2 - 1.2)) and intubation (AOR: 0.3 (0.03 - 2.6)) showed no significant differences in terms of mortality. **Conclusion:**

The in-hospital mortality in COVID-19 patients is very high and hospitalisation into the ICU is associated with even higher mortality. Advanced age, diffused lung involvement (particularly with alveolar consolidation), hemodynamic instability at presentation and altered level of consciousness favoured hospitalisation in the ICU. Once in the ICU, placement on mechanical ventilation did not reduce death discernibly.

**Keywords**

COVID-19, Risk Factors, Mortality, Cameroon

---

**1. Background**

A coronavirus disease also called coronavirus respiratory syndrome, coronavirus pneumonia, coronavirus flu, or any other variant is a disease caused by members of the coronavirus (CoV) family. These include: severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus disease 2019 (COVID-19) [1].

In December 2019, Wuhan city, the capital of Hubei province in China, became the centre of an outbreak of pneumonia of unknown cause [2]. By Jan. 7, 2020, Chinese scientists had isolated a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV, later designed as COVID-19 by World Health Organization (WHO) [3]. By January 11, 2020, the first virus-related death of a 61-year-old man in Wuhan was reported [4].

The 2019-20 coronavirus outbreak was declared a pandemic by the WHO on 11th March 2020 [5]. As of June 21st, 2020, a total of 8,708,008 cases had been documented globally and 461,715 deaths. North America was the most affected region with almost 50% of cases and 47% of deaths, while, Africa had recorded 216,999 cases for 4874 deaths [6]. In Cameroon, the first case was reported on March 6th, 2020, and within days it declared a state of emergency that included travel bans, lockdowns, widespread testing, and quarantine [7]. As of May 30th, 2020, the Ministry of Public Health who regularly communicated on figures at a
national level, reported 5659 persons tested positive, 185 deceased and 3441 recovered cases [8].

The clinical spectrum of SARS-CoV-2 infection appears to be wide, encompassing asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure and even death. Pneumonia mostly occurs in the second or third week of symptomatic infection. Prominent signs of viral pneumonia include decreased oxygen saturation, blood gas deviations, changes visible through chest X-rays and other imaging techniques, with ground glass abnormalities, patchy consolidation, alveolar exudates, and interlobular involvement, eventually indicating deterioration. Blood analysis has shown lymphopenia to be common, and inflammatory markers to be elevated [9] [10].

Recent reports suggest that approximately 14% - 29% of hospitalized patients with COVID-19 pneumonia require intensive care, primarily for respiratory support in the setting of hypoxic respiratory failure, with Acute Respiratory Distress Syndrome (ARDS) developing in 33% of hospitalized patients at a median time from symptom onset of 8 days [11] [12]. In these reports, critically ill patients were older, more likely to be male, and to have underlying comorbidities. Evidence shows that the overall mortality rate of COVID-19 is 3.8% - 5.4%, rate ranged from 8% to 21% among those patients admitted with pneumonia, however, it increases up to 41% - 61% among severe or critically ill patients [13] [14].

Given the rapid spread of COVID-19, and in order to reduce the overall mortality, identifying the risk factors related to disease severity and mortality in COVID-19 patients is urgently required. The present article therefore aimed to provide data describing the factors associated with mortality in COVID-19 patients in a sub-Saharan nation.

2. Materials and Method

2.1. Study Design and Period

This study was a hospital-based cross-sectional retrospective study carried out for four months (March to June 2020).

2.2. Study Area

The study was carried out in Douala, the economic capital of Cameroon, which has the busiest international airport in the country thereby more likely to receive imported cases. It is a cosmopolitan city, recording the largest number of confirmed cases in the country as of the end-date of this study. It is a town with an estimated 3.7 million inhabitants in 2021 [15]. All the critically ill patients requiring Intensive Care Unit (ICU) admission in the region were referred to LHD.

The Laquintinie Hospital of Douala (LHD) was the designated focal point for reception, treatment, and isolation of COVID-19 cases in the Littoral region. It is
a tertiary hospital dispensing extensive medical services and a very important
health structure in the country due to the affordability of its wide range of ser-
VICES, seniority, and surface area. It also serves as a teaching hospital. Along with
the well-equipped 24-hour casualty unit, there exist laboratory, pathology, and
radiologic units. The ICU has a 12-bed capacity, with two ventilators and the
unit is managed by three anaesthesiologists. Two hospital wards each with
100-bed capacity were set aside for isolation of asymptomatic patients and those
with mild to moderate presentations of COVID-19, managed by 40 health person-
nel among which were infectious disease specialists, cardiologists, pneumologists,
and general practitioners.

2.3. Study Population and Sample
Subjects for the study included all COVID-19 patients who were admitted at
LHD from 1st March 2020 to 31st June 2020.

Inclusion Criteria: All confirmed cases of COVID-19 admitted and managed
at LHD during the study period with complete data in files.

Exclusion Criteria: Cases not treated in the hospital, not having a positive
real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) test.

Sample Size: 282 cases were involved in the study.

2.4. Study Procedures
Authorization to carry out this research was obtained from the director of the
Laquintinie Hospital. Ethical clearance was equally sought and gotten from the
Institutional Ethics Committee (IEC) of the hospital. This permitted us to use
both the electronic and physical files of patients consulted and managed in the
hospital during the study period. Anonymity was respected by coding the files
and guaranteed that patient’s names or identification was not to be disclosed on
any study document. We then proceeded to the various wards to have access to
the records of patients treated for this condition. We obtained epidemiological,
demographic, clinical, laboratory, management, and outcome data from pa-
tients’ medical records.

Laboratory confirmation of COVID-19 was being done initially by the Centre
Pasteur du Cameroun, a reference biological laboratory in the country, then by
the hospital’s laboratory. Nasopharyngeal swab samples were collected following
standard safety procedures. The analysis was done by the RT-PCR for suspected
cases following the protocol established by the country which was adapted from
WHO guidelines [16].

In emergency situations, cases with a high clinical and radiological suspicion
were treated as COVID positive similar to situations in other western countries
[17], with PCR confirmation coming afterward. Radiological interpretations of
the chest computed tomography (CT) scans were done by radiologists. The cases
were classified in clinical syndromes as described by WHO in their interim
guidance of March 2020 [16].
The ICU and hospital outcomes of each patient were recorded. The interval from symptom onset to ICU admission, length of ICU stay, rate of intubation, and rate of readmission to ICU were also evaluated. The drug therapy used for all confirmed cases was the same irrespective of severity as was approved by the country’s national guidelines.

In cases of incomplete data from the records, we obtained data by direct communication with attending physicians and other healthcare providers. All data were checked by two physicians.

2.5. Data Management and Analysis

Pre-established data collection sheets were used to collect information on identification, socio-demographic and clinical characteristics, follow-up and outcome. SPSS version 25.0 was used to enter and analyse data. Numerical variables were presented as mean (Standard Deviation (SD)) or median (Interquartile Range (IQR)) or categorized based on reference limits. Meanwhile we summarised categorical variables as frequencies (n), proportions (%) and compared differences in proportions (mortality, which was our outcome of interest) using the Chi’s squared test and the Fisher’s exact test where appropriate. We further compared variables which showed significant associations with mortality using logistic regression models with Odds Ratio (OR) (95% Confidence Interval (CI)) in a stepwise approach. First we exposed crude OR for each of the variables and subsequently made adjustments for being hospitalized into the ICU (Adjusted OR (AOR)). An Alpha value was set at $P = 0.05$.

3. Results

We retrieved 379 files of patients in the hospitalised for COVID-19 within the study period, excluded 97 which did not meet inclusion criteria (either were not admitted or clear reference to positive PCR test was seen) and retained 282 for analysis. 192 (68.1%) were males giving an M: F ratio of 2:1. The mean age was 52 (±15) years. We identified at least one chronic medical condition in 124 cases (44.0%), with hypertension and diabetes accounting for about 75% of these conditions identified (Table 1). The median duration of symptoms before presentation at the hospital was 5 (3 - 10) days. Most cases, 274 (97.2%) reported at least one of the major symptoms investigated with fever, cough, dyspnea, asthenia, and chest pain, contributing to 80.0% of these symptoms. The commonest severe manifestation was severe pneumonia (11.3%), closely followed by sepsis and ARDS (8.5% and 9.2%) respectively. Patients benefited from a first CT scan evaluation averagely on their first day of hospitalization (mean (SD) 0.5 (0.0)), with varying radiological patterns. The most frequent pattern observed was a <10% lung parenchymal involvement (70.6%) with a ground-glass appearance (85.1%) meanwhile a >75% lung involvement occurred in 5.2% of cases. The proportion of cases put on oxygen (via nasal prongs) was 35.5%, often within the first day of hospitalization (Mean (SD): 0.8 (0.0) days). The average duration of
### Table 1. Mortality according to the general characteristics of patients.

| Sociodemographic Characteristic | Total Number of cases (N = 282) | Mortality n (%) | P-Value |
|---------------------------------|---------------------------------|-----------------|---------|
| **Age Groups**                  |                                 |                 |         |
| 1 - 39                          | 64                              | 7 (10.9)        | <0.001  |
| 40 - 49                         | 74                              | 24 (32.4)       |         |
| 50 - 59                         | 52                              | 15 (28.8)       |         |
| 60 - 69                         | 62                              | 30 (48.4)       |         |
| 70+                             | 30                              | 13 (43.3)       |         |
| **Sex**                         |                                 |                 |         |
| Male                            | 192                             | 62 (32.3)       | 0.7     |
| Female                          | 90                              | 27 (30.0)       |         |
| **Diabetes**                    |                                 |                 |         |
| Absent                          | 236                             | 69 (29.2)       | 0.057   |
| Present                         | 46                              | 20 (43.5)       |         |
| **HIV**                         |                                 |                 |         |
| Absent                          | 278                             | 88 (31.7)       | 0.999   |
| Present                         | 4                               | 1 (25)          |         |
| **Obesity**                     |                                 |                 |         |
| Absent                          | 277                             | 87 (31.4)       | 0.652   |
| Present                         | 5                               | 2 (40)          |         |
| **Hypertension**                |                                 |                 |         |
| Absent                          | 197                             | 57 (28.9)       | 0.149   |
| Present                         | 85                              | 32 (37.6)       |         |
| **Chronic Obstructive Lung Disease** |                                 |                 |         |
| Absent                          | 277                             | 88 (31.7)       | 0.999   |
| Present                         | 5                               | 1 (20)          |         |
| **Asthma**                      |                                 |                 |         |
| Absent                          | 274                             | 87 (31.8)       | 0.999   |
| Present                         | 8                               | 2 (25)          |         |
| **Chronic Kidney Disease**      |                                 |                 |         |
| Absent                          | 276                             | 86 (31.2)       | 0.384   |
| Present                         | 6                               | 3 (50)          |         |
| **Cancer**                      |                                 |                 |         |
| Absent                          | 277                             | 86 (31)         | 0.182   |
| Present                         | 5                               | 3 (60)          |         |
| **Other Immunodepressions**     |                                 |                 |         |
| Absent                          | 280                             | 87 (31.7)       | 0.099   |
| Present                         | 2                               | 2 (100)         |         |
| **Sickle cell disease**         |                                 |                 |         |
| Absent                          | 279                             | 89 (31.9)       | 0.554   |
| Present                         | 3                               | 0 (0)           |         |
stay on oxygen was 2.5 (±2) days, delivered at maximum flow rates of 5.7 (±1.9) L/min. Up to 92 (32.6%) patients were admitted to the ICU. Eighty-one (88%) patients were put on non-invasive mechanical ventilation (NIMV), with the mean duration per patient of 3.2 (±2.0) days. The mean duration of hospital stay (LOS) was 10 (±5.2) days; however for patients who died the average LOS was 4.4 days (Table 2).

Out of the 282 cases, 89 patients died, giving an overall mortality of 31.5%. The mortality in patients admitted into the ICU was 54.3% (50/92), compared with 20.5% (32/190) when not admitted into ICU. The average age was 48.8 (SD: 14.8) years among the discharged and 56.4 years (SD: 12.9) among the deceased. Furthermore, mortality ranged from 10.9% in patients <40 year old to 48.4% in those 60 - 69 year old (Table 1). Overall, patients aged 0 - 39 years had a significantly lesser odd of mortality compared with those >70 years (OR: 0.2 (0.1 - 0.5) P < 0.001) and this was the same when we considered only cases admitted into the ICU (Table 3). Meanwhile mortality was approximately equal in males and females. Also, those with chronic medical conditions such as diabetes and hypertension experienced higher mortality (Table 1).

Clinical and para-clinical evaluation revealed that mortality varied significantly according to the hemodynamic states at time of presentation, the clinical syndromes observed, CT scan image patterns and the proportion of lung parenchyma involved. Mortality following hemodynamic disturbances identified at time of presentation was as follows; 51.1% in patients presenting with a respiratory rate >35 breaths/min; up to 87.8% of those with oxygen saturations <75%; 55.5% of those with pulse rates >126 beats per minute and 43.1% in those with temperatures >38.5˚C. All patients (6) presenting with a GCS < 13 died. ARDS was observed in 25 patients, 84% of whom died (OR: 133.4 (33.1 - 537.3) P < 0.001) (Table 3).

In addition, mortality was as high as 63% in those with CT scan image patterns showing alveolar consolidation and 85% when lung involvement was 75% - 100%. In the presence of alveolar consolidation patterns the odds of mortality was 3.3 times higher compared to its absence (Table 2). Also a 75% - 100% involvement of the lung parenchyma on CT-scan was associated with odds of mortality which were 50 times that when only <10% of lung parenchyma was involved. In both previous situations, there were no obvious changes in the OR when we considered only patients admitted into the ICU (Table 3). Two cases were identified with pulmonary embolism and they both died during hospitalisation, however not significant.

One-third of the patients presented in a state requiring supplemental oxygen therapy, 55% of them died, meanwhile those not placed on oxygen experienced 18.7% mortality. Whereas 44.5% of patients on NIMV survived and only 20% of intubated patients were discharged from the ICU (Table 2). Patients presenting a state requiring supplemental oxygen (by mask or prongs) had an odds of mortality which was 5 times that of those not placed on oxygen at any point during
Table 2. Mortality according to clinical, paraclinical and treatment options in patients.

| Clinical Characteristics | Total Number of Cases | Mortality n (%) | P-Value |
|--------------------------|-----------------------|-----------------|---------|
| **Respiratory Rate (breath/min) N = 250** |                       |                 |         |
| <12                      | 0                     | -               |         |
| 12 - 24                  | 90                    | 6 (6.7)         | <0.001 |
| 25 - 34                  | 113                   | 32 (28.3)       |         |
| 35+                      | 47                    | 24 (51.1)       |         |
| **Oxygen Saturation (%) N = 279** |                       |                 |         |
| 0 - 75                   | 49                    | 43 (87.8)       |         |
| 76 - 85                  | 44                    | 26 (59.1)       | <0.001 |
| 86 - 93                  | 76                    | 10 (13.2)       |         |
| 94+                      | 110                   | 7 (6.4)         |         |
| **Pulse Rate (bpm) N = 278** |                       |                 |         |
| <125                     | 260                   | 79 (30.4)       | 0.017   |
| 126+                     | 18                    | 10 (55.6)       |         |
| **Systolic Blood Pressure (mmHg) N = 278** |                       |                 |         |
| 0 - 90                   | 4                     | 2 (50)          | 0.588   |
| 90+                      | 274                   | 83 (29.9)       |         |
| **Diastolic Blood Pressure (mmHg) N = 278** |                       |                 |         |
| 0 - 60                   | 12                    | 3 (25)          | 0.999   |
| 60+                      | 266                   | 82 (30.8)       |         |
| **Temperature (°C) N = 275** |                       |                 |         |
| 0 - 38.5                 | 210                   | 54 (25.1)       | 0.007   |
| 38.6+                    | 65                    | 28 (43.1)       |         |
| **Glasgow Coma Score N = 282** |                       |                 |         |
| 3 - 8                    | 0                     | -               | <0.001  |
| 9 - 13                   | 6                     | 6 (100)         |         |
| 14+                      | 276                   | 83 (30.1)       |         |
| **WHO severity Classification (Clinical Syndromes) N = 282** |                       |                 |         |
| Mild disease             | 132                   | 5 (3.8)         |         |
| Moderate disease         | 54                    | 12 (22.2)       |         |
| Severe Pneumonia         | 33                    | 21 (63.6)       | <0.001  |
| ARDS                     | 25                    | 21 (84)         |         |
| Sepsis                   | 27                    | 25 (92.6)       |         |
| Septic Shock             | 8                     | 5 (62.5)        |         |
| **Ground-Glass Patterns N = 282** |                       |                 |         |
| Absent                   | 42                    | 10 (23.8)       | 0.241   |
| Present                  | 240                   | 79 (32.9)       |         |
| **Reticulonodular Patterns N = 282** |                       |                 |         |
| Absent                   | 279                   | 89 (31.9)       | 0.554   |
| Present                  | 3                     | 0 (0)           |         |
hospitalisation. Similarly, placement on NIMV was associated with odds of mortality which were 5 times that of those not placed on it (OR: 0.2 (0.1 - 0.4) P < 0.001). However, when we considered just patients admitted into the ICU, odds of mortality following placement on NIMV were only twice that for those who were not, and this was not significant. Finally intubation was associated with odds of mortality which were 10 times that of those who were not intubated, but when considering just cases in the ICU this was only 3.3 times higher and not significant (Table 3).

4. Discussion

Our study compared the demographic and clinical data, laboratory findings, radiological characteristics, and complications between COVID-19 patients who died or were discharged and evaluated the risk factors for mortality in a single center in Douala, Cameroon. We found that, mortality was very high in hospitalized COVID-19 patients especially in ICU cases, and that old age together with a wide range of clinical and para-clinical features were associated with mortality.

The mortality rate in our study was 31.5% which was similar to values obtained in Burkina Faso but higher than values obtained from China [14] [18]
Table 3. Association between certain patient characteristics and mortality.

| Patient Characteristics          | Unadjusted values | Adjusted Values (Adjusted for hospitalisation into ICU) |
|---------------------------------|-------------------|--------------------------------------------------------|
|                                 | OR (95% CI)       | P-Value       | OR (95% CI)       | P-Value       |
| Age Groups                      |                   |              |                   |              |
| 1 - 39                          | 0.2 (0.1 - 0.5)   | **0.001**    | 0.2 (0.1 - 0.5)   | **0.002**    |
| 40 - 49                          | 0.6 (0.3 - 1.5)   | 0.295        | 0.7 (0.3 - 1.7)   | 0.399        |
| 50 - 59                          | 0.5 (0.2 - 1.4)   | 0.185        | 0.6 (0.2 - 1.5)   | 0.244        |
| 60 - 69                          | 1.2 (0.5 - 2.9)   | 0.649        | 1.3 (0.5 - 3.4)   | 0.557        |
| 70+                              | -                 |              |                   |              |
| Alveolar Consolidation          |                   |              |                   |              |
| Absent                          | 0.3 (0.1 - 0.6)   | **0.004**    | 0.3 (0.1 - 0.7)   | **0.01**     |
| Present                         | -                 |              |                   |              |
| Parenchymal Involvement         |                   |              |                   |              |
| <10%                            | 0.02 (0.01 - 0.06) | <0.001      | 0.03 (0.01 - 0.1) | <0.001      |
| 10% - 25%                       | 0.3 (0.1 - 0.9)   | **0.026**    | 0.3 (0.1 - 0.96)  | **0.042**    |
| 75% - 100%                      | -                 |              |                   |              |
| WHO severity Classification     |                   |              |                   |              |
| (Clinical Syndromes)            |                   |              |                   |              |
| Septic Shock                    | 42.3 (7.8 - 228.8) | <0.001      | 56.6 (9.1 - 353.6) | <0.001      |
| Sepsis                          | 317 (58.3 - 1729.3) | <0.001      | 393.7 (66.2 - 2340.4) | <0.001      |
| ARDS                            | 133.4 (33.1 - 537.3) | <0.001      | 165.6 (37.0 - 740.5) | <0.001      |
| Severe Pneumonia                | 30.5 (9.9 - 93.9)  | <0.001      | 37.5 (10.9 - 128.9) | <0.001      |
| Moderate disease                | 7.3 (2.4 - 21.8)  | <0.001      | 8.1 (2.6 - 25.1)   | <0.001      |
| Mild disease                    | -                 |              |                   |              |
| Oxygen Therapy                  |                   |              |                   |              |
| No                              | 0.2 (0.1 - 0.3)   | <0.001      | 0.2 (0.1 - 0.4)   | <0.001      |
| Yes                             | -                 |              |                   |              |
| Non-invasive MV                 |                   |              |                   |              |
| No                              | 0.2 (0.1 - 0.4)   | <0.001      | 0.5 (0.2 - 1.2)   | **0.126**   |
| Yes                             | -                 |              |                   |              |
| Invasive MV                     |                   |              |                   |              |
| No                              | 0.1 (0.01 - 1.0)  | 0.051        | 0.3 (0.03 - 2.6)   | 0.264        |
| Yes                             | -                 |              |                   |              |

[19] this difference could be explained by the fact that hospital admissions in Africa usually consisted of severe cases compared to China, the late presentation of patients in hospitals and also the higher standard of care in China. This mortality however rose to 54% among the critically ill patients, as reported in other studies [11] [12] [20] the reasons for which may differ, in our context, the absence of ventilators and few beds in the ICU may explain this increase.

Our data showed that patients who died were older similar to what was reported worldwide. Bellani et al. [21] [22] explains that old patients mostly men with viral pneumonia easily develop ARDS which could eventually be fatal to
them. This study confirmed that old age was associated with death in patients with COVID-19. For example cases older than 70 year old had a 5-fold odds of mortality compared with those younger than 40 year old. More so, when we considered just cases hospitalised into the ICU, the association between old age and mortality remained unchanged suggesting advanced age strongly favoured transfer into ICU and consequently death.

Although we had more male patients and more deaths in absolute terms in this population, the male and female mortality showed no significant difference, this however contrasts with most studies seen which showed a male sex associated with mortality [14] [20] [23].

Our findings support the observations of earlier studies [11] [14] [24], which found a high percentage of hospitalized patients of advance age with pre-existing conditions, hypertension and diabetes being the most common among the deceased.

Our study showed that severe tachypnea and tachycardia were associated with mortality paralleling other observation [25]. Almost half of those with elevated temperature on admission ended up dying. This turned out to be a factor of poor outcome in our population matching findings of different study [13], delay of fever manifestation hinders early identification of patients, fever being an unspecific symptom patients may have attempted to treat as another disease and therefore delays management. Altered level of consciousness was shown by a very few number of cases (2%), but it however showed significant association with mortality. Zhang et al. [14] had a similar observation. Altered level of consciousness is a feature of severe pneumonia and may be due to hypoxemia. It also hinders patient from seeking care and leads to loss of protective reflexes and could lead to aspirations further decompensating the situation.

ARDS in our study just like others [26] [27] showed similar mortality. Along with severe sepsis and shock were considered severe presentations and were shown to be associated with mortality similar to other studies [14]. Patients with severe illness may develop dyspnoea and hypoxemia within 1 week after onset of the disease, which may quickly progress to ARDS, end-organ failure and eventually death, giving limited time for response. Furthermore effective therapies may be limited by lack of recognition of ARDS by clinicians [21].

In accordance with most of the recent studies [28] [29], the most common CT features of COVID-19 included bilateral ground-glass opacity and alveolar consolidation. Presence of consolidation patterns was associated with mortality, similar to Zhang et al. [19]. Having 75% - 100% of lung parenchyma affected also led to increase mortality as this observation attained statistical significance. This was probably because the damage to the entire lungs, as well as the ensuing fibrosis decreased the available surface area for gas exchange. This prejudice increased risk of death.

Poor oxygen saturation and presence of respiratory distress were main signs which prompted oxygen therapy to be initiated. A third of the population re-
received oxygen supplementation as part of their treatment. This however was associated with mortality after univariate analysis. Skrip et al. [18] however arrived at a different conclusion. Furthermore when we considered just cases hospitalised into the ICU, the association between placement on oxygen and mortality remained unchanged suggesting presentation with clinical states requiring oxygen, strongly favoured transfer into ICU and consequently death.

There was an association between transfer to the ICU and mortality, this was 2.5 times higher than mortality in the general ward. The findings were similar to those obtained in international studies [21] [23] but differed from results of other studies [11] [26]. The high incidence of critical illnesses among hospitalised patients has acute implications for our hospital systems, specifically the potential need to increase equipment and ICU surge capacity in preparation for large numbers of patients requiring IMV and other forms of organ support.

Overall, being placed on mechanical ventilation at any point, be it invasive or not showed association with mortality. 90% of ICU patients were placed on non-mechanical ventilation similar to other cohorts [20] while only 5% went on to be intubated which was far less than other settings. However, when we limited comparisons just to patients hospitalised into the ICU, we found no significant differences in mortality for those placed on mechanical ventilation (both non-invasive and invasive) compared with those not placed on it. This affirms that hospitalisation into the ICU strongly favoured death and subsequent placement on these treatment modalities did not reduce death significantly. Mechanical ventilation particularly invasive is the main supportive treatment for critically ill patients.

**Study Limitations**

Laboratory investigations, ECGs and other pertinent information which could have affected mortality were not accessed in this study due to unavailability.

Our study is a single centre study, interpretation of our findings might be limited by the sample size, when compared to the national numbers, therefore limiting generalizability to the entire country.

**5. Conclusions**

The in-hospital mortality in COVID-19 patients is very high and hospitalisation into the ICU is associated with even higher mortality. Old age, diffused lung involvement (particularly with alveolar consolidation), hemodynamic instability at presentation, altered level of consciousness, ARDS and severe sepsis favoured hospitalisation in the ICU. Once in the ICU, placement on mechanical ventilation did not reduce death discernibly.

**What is already known on this topic?**

- It is a global pandemic with elevated mortality worldwide.
- It is a highly infectious disease requiring addition preventive measures to reduce risk of infection.

**What this study adds:**
- The description and analysis of factors affecting mortality in a sub-Saharan population.
- Gives an objective explanation from a scientific angle of the reasons which contributed to the mortality in our community.

**Recommendations**

More resources should be invested by researchers towards finding solutions to curb mortality especially among the critical ill patient, in aspects such as prevention with vaccines, also multicentre studies with larger sample size to make results more generalizable.

Close follow up of patients’ parameters by health personnel might aid in early identification of disease severity and subsequently reduce mortality, also early initiation on oxygen therapy and intubations accordingly.

**Acknowledgements**

We are grateful to the staff of the Laquintinie Hospital Douala for their steadfast dedication to the management of patients affected by the COVID-19 pandemic as well as all healthcare professionals involved in the fight against COVID-19 and also to all persons who contributed to the end result of this research.

**Author Contribution**

FAB, MC, EA, DM, HL, JZM and MNN designed the study. FAB, CN, MT, MSN, MLE and DM collected data at LHD. MC, EEN, DA and CE conducted the data simulation. FAB and MC conducted the data analysis. FAB, MC, EA and JZM wrote the first draft of the manuscript. All authors contributed intellectually and made contributions to the manuscript text.

**Funding**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing Interest**

The authors declare that they have no competing of interests.

**References**

[1] WHO. Naming the Coronavirus Disease (COVID-19) and the Virus that Causes It. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-19)-and-the-virus-that-causes-it

[2] Upadhyaya, A., Koirala, S., Ressler, R. and Upadhyaya, K. (2020) Factors Affecting COVID-19 Mortality: An Exploratory Study. Journal of Health Research, 36. https://doi.org/10.1108/JHR-09-2020-0448

[3] Maru, E.H., Leulseged, T.W., Hassen, I.S., Zewde, W.C., Chamesew, N.W., et al. (2020) Predictors of Death in Severe COVID-19 Patients at Millennium COVID-19 Care Center in Ethiopia: A Case-Control Study. MedRxiv.
Advances in Infectious Diseases

https://www.medrxiv.org/content/10.1101/2020.10.07.20205575v1

[4] Muccari, R., Chow, D. and Murphy, J. (2021) Coronavirus Timeline: Tracking the Critical Moments of Covid-19. NBC News. https://www.nbcnews.com/health/health-news/coronavirus-timeline-tracking-critical-moments-covid-19-n1154341

[5] Ngeh, E.N. and Kuaban, C. (2020) COVID-19: Challenges and the Impact on Care in Clinical Settings in Cameroon. The Pan African Medical Journal, 35, Article No. 122.

[6] WHO (2020) Coronavirus Disease: Situation Report-153. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200621-covid-19-sitrep-153.pdf?sfvrsn=c896464d_2

[7] Mekolo, D., Bokalli, F.A., Chi, M.F., Fonkou, S.B., Takere, M.M., et al. (2021) Clinical and Epidemiological Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Douala, Cameroon. The Pan African Medical Journal, 38, Article No. 246.

[8] OCHA (2021) Cameroun: Rapport de situation, 29 mars 2021. https://reliefweb.int/report/cameroon/cameroun-rapport-de-situation-29-mars-2021

[9] Velavan, T.P. and Meyer, C.G. (2020) The COVID-19 Epidemic. Tropical Medicine & International Health, 25, 278-280. https://doi.org/10.1111/tmi.13383

[10] Fouda, M., Halle, M.P., Mbele, O.C., Mbatchesou, B.H., Luma, N.H. and Ashuntantang, E.G. (2021) Profil épidémiologique et clinique, et survie à 90 jours des patients incidents en hémodialyse chronique au cours de la pandémie à SARS-CoV2 au Cameroun: Expérience de l'hôpital général de Douala. Néphrologie & Thérapeutique, 17, 226-232. https://doi.org/10.1016/j.nephro.2020.12.002

[11] Suleyman, G., Fadel, A.R., Malette, K.M., et al. (2020) Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Network Open, 3, e2012270. https://doi.org/10.1001/jamanetworkopen.2020.12270

[12] Yang, X.B., Yu, Y., Xu, J.Q., Shu, H.Q., Xia, J.A., et al. (2020) Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. The Lancet Respiratory Medicine, 8, 475-481. https://doi.org/10.1016/S2213-2600(20)30079-5

[13] Feng, Y., Ling, Y., Bai, T., Xie, Y., et al. (2020) COVID-19 with Different Severities: A Multicenter Study of Clinical Features. American Journal of Respiratory and Critical Care Medicine, 201, 1380-1388.

[14] Zhang, J., Wang, X., Jia, X., Li, J., Hu, K., et al. (2020) Risk Factors for Disease Severity, Unimprovement, and Mortality in COVID-19 Patients in Wuhan, China. Clinical Microbiology and Infection, 26, 767-772. https://doi.org/10.1016/j.cmi.2020.04.012

[15] United Nations. World Urbanization Prospects 2018. https://population.un.org/wup/

[16] WHO (2020) Clinical Management of COVID-19. https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19

[17] Desvaux, É. and Faucher, J.F. (2020) Covid-19: Aspects cliniques et principaux éléments de prise en charge. Revue Francophone des Laboratoires, 2020, 40-47. https://www.em-consulte.com/article/1402285/covid-19-aspects-cliniques-et-princi
18. Skrip, L., Derra, K., Kabore, M., Noori, N., Gansane, A., et al. (2020) Clinical Management and Mortality among COVID-19 Cases in Sub-Saharan Africa: A Retrospective Study from Burkina Faso and Simulated Case Analysis. *International Journal of Infectious Diseases*, 101, 194-200. [https://doi.org/10.1016/j.ijid.2020.09.1432](https://doi.org/10.1016/j.ijid.2020.09.1432)

19. Zhang, X.B., Hu, L., Ming, Q., Wei, X.J., Zhang, Z.Y., et al. (2021) Risk Factors for Mortality of Coronavirus Disease-2019 (COVID-19) Patients in Two Centers of Hubei Province, China: A Retrospective Analysis. *PLoS ONE*, 16, e0246030. [https://doi.org/10.1371/journal.pone.0246030](https://doi.org/10.1371/journal.pone.0246030)

20. Cummings, M.J., Baldwin, M.R., Abrams, D., Jacobson, S.D., Meyer, B.J., et al. (2020) Epidemiology, Clinical Course, and Outcomes of Critically Ill Adults with COVID-19 in New York City: A Prospective Cohort Study. *The Lancet*, 395, 1763-1770. [https://doi.org/10.1016/S0140-6736(20)31189-2](https://doi.org/10.1016/S0140-6736(20)31189-2)

21. Bellani, G., Laffey, J.G., Pham, T., Fan, E., Brochard, L., et al. (2016) Epidemiology, Patterns of Care, and Mortality for Patients with Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. *JAMA*, 315, 788-800. [https://doi.org/10.1001/jama.2016.0291](https://doi.org/10.1001/jama.2016.0291)

22. Ombojo, L.A., Mutono, N., Sudi, P., Mutua, M., Sood, M., Loo, A.M.A., et al. (2020) Epidemiological and Clinical Characteristics of COVID-19 Patients in Kenya. MedRxiv. [https://www.medrxiv.org/content/10.1101/2020.11.09.20228106v1](https://www.medrxiv.org/content/10.1101/2020.11.09.20228106v1)

23. Grasselli, G., Greco, M., Zanella, A., Alban, G., et al. (2020) Risk Factors Associated With Mortality among Patients with COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Internal Medicine*, 180, 1345-1355. [https://doi.org/10.1001/jamainternalmed.2020.3539](https://doi.org/10.1001/jamainternalmed.2020.3539)

24. Paitraud, D. (2021) Risque de COVID19 sévère et de décès: Les résultats d’une vaste étude de cohorte française. VIDAL France. [https://www.vidal.fr/actualites/26615-risque-de-covid-19-severe-et-de-deces-les-resultats-d-une-vaste-etude-de-cohorte-francaise.html](https://www.vidal.fr/actualites/26615-risque-de-covid-19-severe-et-de-deces-les-resultats-d-une-vaste-etude-de-cohorte-francaise.html)

25. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., et al. (2020) Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. *The Lancet*, 395, 1054-1062. [https://doi.org/10.1016/S0140-6736(20)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)

26. Cao, J., Tu, W.J., Cheng, W., Yu, L., Liu, Y.K., et al. (2020) Clinical Features and Short-Term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China. *Clinical Infectious Diseases*, 71, 748-755. [https://doi.org/10.1093/cid/ciaa243](https://doi.org/10.1093/cid/ciaa243)

27. Wu, C.M., Chen, X.Y., Cai, Y.P., Xia, J.A., Zhou, X., et al. (2020) Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Internal Medicine*, 180, 934-943. [https://doi.org/10.1001/jamainternalmed.2020.0994](https://doi.org/10.1001/jamainternalmed.2020.0994)

28. Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England Journal of Medicine*, 382, 1708-1720. [https://doi.org/10.1056/NEJMoa2002032](https://doi.org/10.1056/NEJMoa2002032)

29. Niang, I., Dialli, I., Diouf, J.C., Ly, M., Hamine, M., et al. (2020) Tri et détection du COVID-19 par TDM thoracique low-dose chez des patients tout-venant au service de radiologie de l’hôpital de Fann (Dakar-Sénégal). *The Pan African Medical Journal*, 37, Article No. 22.
APPENDICES

Data Collection Form
COHORTE OBSERVATIONNELLE COVID-19
Centre: _____________________________
Investigateur: _____________________________
Nom patient: I___I (première lettre)   Prénom patient: I___I (première lettre)
Date de naissance: |__|__| /|__|__| /|__|__|__|__| (jour/mois/année)
Sexe: ☐ masculin ☐ féminin
Taille: I___I___I___I cm    Poids corporel: I___I___I___I kg

Admission
• Date d'entrée dans l'hôpital: |__|__| /|__|__| /|__|__|__|__| (jour/mois/année)

Antécédents médicaux

Tabagisme (actif ou sevré): ☐ Non-Fumeur ☐ Ancien ☐ Actif ☐ ND
Si actif, préciser le nombre de paquets-années: |__|__|__| ou ☐ ND

Pathologie respiratoire chronique:
☐ Oui ☐ Non
Si oui: BPCO (BronchoPneumonie Chronique Obstructive)
☐ Oui ☐ Non

Asthme
☐ Oui ☐ Non

Insuffisance cardiaque systolique (fraction d’éjection < 45%)
☐ Oui ☐ Non

Autre insuffisance cardiaque chronique
☐ Oui ☐ Non

Insuffisance rénale chronique
☐ Oui ☐ Non
Si oui: Epuration extra-rénale chronique
☐ Oui ☐ Non

Cirrhose
☐ Oui ☐ Non

Cancer ou hémopathie
☐ Oui ☐ Non

Autre Immunodépression
☐ Oui ☐ Non

Drépanocytose
☐ Oui ☐ Non

ECHELLE DE FRAGILITE HABITUELLE (avant la maladie actuelle)
☐ Très en forme ☐ En forme ☐ Se débrouille bien
☐ Vulnérables ☐ Légèrement fragile ☐ Modérément fragiles
☐ Sévèrement fragiles ☐ Très sévèrement fragiles ☐ En phase terminale

INFECTION COVID-19
• Date des premiers symptômes: |__|__| /|__|__| /|__|__|__|__| (jour/mois/année)

Symptômes:
☐ Fièvre (T > 38.2˚C) ☐ Toux ☐ Dyspnée
☐ Douleur thoracique ☐ Malaise ☐ Rhinorrhée
☐ Arthralgie ☐ Céphalée ☐ Diarrhée
☐ Vomissement ☐ Myalgie
Diagnostic confirmé par PCR: ☐ Oui ☐ Non
Si oui, date: |__|__| / |__|__| / |__|__|__|__|
(jour/mois/année)

Diagnostic scanographique ☐ Oui ☐ Non
Si oui:
  ○ Date: |__|__| / |__|__| / |__|__|__|__|
  (jour/mois/année)
  ○ Pattern:
    □ Verre dépoli □ Syndrome réticulo-nodulaire □ Syndrome de condensation alvéolaire
  ○ Prédominance inférieure: ☐ Oui ☐ Non
  ○ Nombre de lobes touchés: |__|
  ○ Pourcentage de parenchyme atteint:
    □ <10% □ 10% - 25% □ 25% - 50% □ 50% - 75% □ >75%
  ○ Embolie pulmonaire: ☐ Oui ☐ Non ☐ scanner non injecté

DONNEES CLINIQUES A L’ADMISSION
Données recueillies au cours des 24 h suivant l’admission (pires valeurs):

• Fréquence respiratoire (cycles /min) |__|__|
• SpO2 (%) |__|__|
• Fréquence cardiaque (bpm) |__|__|
• Pression artérielle systolique (mm Hg) |__|__|
• Pression artérielle diastolique (mm Hg) |__|__|
• Température (˚C) |__|__|
• Score de Glasgow |__|__|

DONNEES BIOLOGIQUES A L’ADMISSION
Données recueillies au cours des 24 h suivant l’admission (pires valeurs):

• Gaz du sang: ☐ Oui ☐ Non
  Si oui, condition de réalisation: ☐ Air ambiant ☐ Oxygène: |__|__|L/min
  pH |__|__| CO2t |__|__| mmol/L Lactates |__|__| mmol/L
  PaO2 |__|__| mm Hg PaCO2 |__|__| mm Hg SaO2 |__|__|
• Urée |__|__| mmol/L ☐ NA
• Créatinine |__|__| µmol/L ☐ NA
• CPK |__|__|__| | UI/L ☐ NA
• LDH |__|__| | UI/L ☐ NA
• ASAT |__|__| | UI/L ☐ NA
• ALAT |__|__| | UI/L ☐ NA
• PAL |__|__| | UI/L ☐ NA
• γGT |__|__| | UI/L ☐ NA
• Bilirubine totale |__|__| mmol/L ☐ NA
• Bilirubine conjuguée |__|__| mmol/L ☐ NA
• Leucocytes |__|__| | G/L ☐ NA
• Lymphocytes |__|__| | G/L ☐ NA
• PNN |__|__| | G/L ☐ NA
• Plaquettes |__|__| | G/L ☐ NA
MODALITÉS DE LA PRISE EN CHARGE RESPIRATOIRE

- **Mise sous oxygène:**
  - Oui ☐
  - Non ☐
  
  **Si oui,**
  
  Date de début: [__] [__] [__]/[__] [__] [__]
  
  Date de fin: [__] [__] [__]/[__] [__] [__]
  
  (jour/mois/année)
  
  Débit maximal O₂: [__] [__] L/min
  
  Cause arrêt: ☐ Sevrage (amélioration) ☐ Passage à CPAP/VNI ☐ Intubation ☐ Décès

- **Mise sous CPAP:**
  - Oui ☐
  - Non ☐
  
  **Si oui,**
  
  Date de début: [__] [__] [__]/[__] [__] [__]
  
  Date de fin: [__] [__] [__]/[__] [__] [__]
  
  (jour/mois/année)
  
  Débit maximal O₂: [__] [__] L/min
  
  Cause arrêt: ☐ Sevrage (amélioration) ☐ Intubation ☐ Décès

- **Mise sous Ventilation Non Invasive:**
  - Oui ☐
  - Non ☐
  
  **Si oui,**
  
  Date de début: [__] [__] [__]/[__] [__] [__]
  
  Date de fin: [__] [__] [__]/[__] [__] [__]
  
  (jour/mois/année)
  
  Valeur maximale FiO₂: [__] [__] [%]
  
  Cause arrêt: ☐ Sevrage (amélioration) ☐ Intubation ☐ Décès

- **Intubation ventilation mécanique:**
  - Oui ☐
  - Non ☐
  
  **Si oui,**
  
  Date de début: [__] [__] [__]/[__] [__] [__]
  
  Date de fin: [__] [__] [__]/[__] [__] [__]
  
  (jour/mois/année)
  
  Valeur maximale FiO₂: [__] [__] [%]
  
  Rapport PaO₂/FiO₂ le plus bas dans les 24 h suivant l’intubation: [__] [__] [__]
  
  Le patient a-t-il été extubé? oui ☐ non ☐
  
  o Si oui, date d’extubation sans ré-intubation dans les 72 heures: [__] [__] [__]/[__] [__] [__]

**TRAITEMENT SPÉCIFIQUE DURANT L’HOSPITALISATION**

- Lopinavir/ritonavir               oui ☐ non ☐
- Chloroquine/Hydroxychloroquine   oui ☐ non ☐
- Corticothérapie                  oui ☐ non ☐
- Tocilizumab                      oui ☐ non ☐
- Antibiotique                     oui ☐ non ☐

Si oui, préciser: __________________________________________________________

**SUIVI A J 28**

Le patient est-il toujours à l’hôpital? oui ☐ non ☐

**Si sortie d’hôpital: date: [__] [__] [__]/[__] [__] [__]**
Le patient a-t-il été admis en réanimation? oui ☐ non ☐
• Si admission en réanimation:
  o Date d’admission: [__|__| /|__|__| /|__|__|__|__|]
  o Le patient est-il toujours en réanimation? oui ☐ non ☐
  o Si non, Date de sortie de réanimation: [__|__| /|__|__| /|__|__|__|__|]
Le patient a-t-il nécessité une perfusion de catécholamines ? oui ☐ non ☐
• Si perfusion de catécholamines:
  o Type de catécholamine:
    dopamine ☐ dobutamine ☐ noradrenaline ☐ adrenaline ☐
  o Date de début catecholamines: [__|__| /|__|__| /|__|__|__|__|]
  o Date de fin catecholamines: [__|__| /|__|__| /|__|__|__|__|]
Le patient a-t-il nécessité une épuration extra-rénale? oui ☐ non ☐
• Si épuration extra-rénale:
  o Date de début épuration: [__|__| /|__|__| /|__|__|__|__|]
  o Date de fin épuration: [__|__| /|__|__| /|__|__|__|__|]
Le patient est-il décédé? oui ☐ non ☐
Si décès: date: [__|__| /|__|__| /|__|__|__|__|]